Two patients die in now-halted study of Audentes gene therapy | BioPharma Dive

While other gene therapy studies have been stopped in recent years, the deaths observed in Audentes’ trial are particularly worrisome.

On May 6, Audentes told the groups that a patient treated with a high dose of AT132 had died from sepsis. Two others also given the high dose had then experienced serious side effects.

Six weeks later, on June 23, Audentes CEO Natalie Holles and chief medical officer Edward Conner sent a second letter explaining that one of those two had also died. 

Two patients die in now-halted study of Audentes gene therapy | BioPharma Dive